Pfizer vaccine trial a 'promising first step'
Pfizer and a German partner released data Thursday on an experimental coronavirus vaccine they say produced an immune response in healthy patients.
this morning. New evidence We may be one step closer to an effective Corona virus vaccine. On Wednesday, Pfizer and its German biotech partner by on tak releasing new clinical data on their experimental vaccine, showing it spurred immune responses in healthy patients. 45 healthy people between the ages of 18 and 55 took part in the trial. 24 were given. Two doses of the vaccine in all developed higher levels of antibodies than typically seen in recovered patients. N Y u Chief of infectious disease doctor Mark Mulligan is leading the trial. What we found was it produced an antibody response, including neutralizing antibodies in 100% of people that received the vaccine. This is a a promising, encouraging first step, but it's not a slam down. More than half of patients who received a dose reported side effects, including fever and sleep disturbances deemed non serious by Fizer. Yoga instructor Melissa Han Kanin was one of the first healthy volunteers to get the injection. After the second does, I felt a little bit a key and a my temperature is elevated, so I took a Tylenol and l better. Pfizer's vaccine is one of 17 currently in clinical trials around the world. It works by altering the virus's genetic code, instructing the body to make antibodies without exposing people to the virus itself. Still, to be determined whether higher antibody levels lead to immunity to the virus. Unfortunately, that just takes high. You have to watch for a period of time before you could tell, so it is too early to say. Two more larger trials are needed before possible approval, researchers say. Further testing is also planned on a more diverse group of volunteers, including the elderly, people of color and pregnant women. We need to do full scale, face three clinical trials in order to get a full sense of the safety of these vaccines, as well as their ability to actually protect against infection. Miguel Almaguer, NBC News, Los Angeles